165 related articles for article (PubMed ID: 23317985)
1. Octreotide-responsive necrolytic migratory erythema in a patient with pseudoglucagonoma syndrome.
Virani S; Prajapati V; Devani A; Mahmood MN; Elliott JF
J Am Acad Dermatol; 2013 Feb; 68(2):e44-6. PubMed ID: 23317985
[No Abstract] [Full Text] [Related]
2. Rapid Clearance of Necrolytic Migratory Erythema Following Intravenous Administration of Amino Acids.
Thomaidou E; Nahmias A; Gilead L; Zlotogorski A; Ramot Y
JAMA Dermatol; 2016 Mar; 152(3):345-6. PubMed ID: 26581030
[No Abstract] [Full Text] [Related]
3. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
Lo CH; Ho CL; Shih YL
QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
[No Abstract] [Full Text] [Related]
4. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
Tseng HC; Liu CT; Ho JC; Lin SH
Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
Oberkirchner U; Linder KE; Zadrozny L; Olivry T
Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
[TBL] [Abstract][Full Text] [Related]
6. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine.
Jiménez-Gallo D; Ossorio-García L; de la Varga-Martínez R; Arjona-Aguilera C; Linares-Barrios M
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508546
[No Abstract] [Full Text] [Related]
7. A serpiginous eruption.
Esdaile BA; Hollowood K; Burge S
Arch Dermatol; 2012 Mar; 148(3):385-90. PubMed ID: 22431782
[No Abstract] [Full Text] [Related]
8. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
[TBL] [Abstract][Full Text] [Related]
9. Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome.
Moreno-Suárez F; Pulpillo-Ruiz Á; Fontillón Alberdi M
Med Clin (Barc); 2017 Apr; 148(8):e45. PubMed ID: 27567335
[No Abstract] [Full Text] [Related]
10. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome.
Otto AI; Marschalko M; Zalatnai A; Toth M; Kovacs J; Harsing J; Tulassay Z; Karpati S
J Am Acad Dermatol; 2011 Aug; 65(2):458-459. PubMed ID: 21763589
[No Abstract] [Full Text] [Related]
11. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema.
Bewley AP; Ross JS; Bunker CB; Staughton RC
Br J Dermatol; 1996 Jun; 134(6):1101-4. PubMed ID: 8763433
[TBL] [Abstract][Full Text] [Related]
12. Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.
V'lckova-Laskoska M; Balabanova-Stefanova M; Arsovska-Bezhoska I; Caca-Biljanovska N; Laskoski D
Acta Dermatovenerol Croat; 2018 Dec; 26(4):329-332. PubMed ID: 30665484
[TBL] [Abstract][Full Text] [Related]
13. Image Gallery: Necrolytic migratory erythema associated with glucagonoma.
Aragón-Miguel R; Prieto-Barrios M; Calleja-Algarra A; Pinilla-Martin B; Rodriguez-Peralto J; Ortiz-Romero P; Rivera-Diaz R
Br J Dermatol; 2019 Jan; 180(1):e1. PubMed ID: 30604550
[No Abstract] [Full Text] [Related]
14. Glucagonoma syndrome with atypical necrolytic migratory erythema.
He S; Zeng W; Geng S; Jia J
Indian J Dermatol Venereol Leprol; 2021; 87(1):49-53. PubMed ID: 31368453
[TBL] [Abstract][Full Text] [Related]
15. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
[No Abstract] [Full Text] [Related]
16. Paradoxical presentation of glucagonoma with delayed onset of necrolytic migratory erythema.
Gaiser CA; Dhawan N
Am J Med; 2015 Feb; 128(2):e1-2. PubMed ID: 25448171
[No Abstract] [Full Text] [Related]
17. Glucagonoma Syndrome: A Rare Paraneoplastic Disorder due to Neuroendocrine Tumor of the Pancreas.
Yusuf MA; Mehmood S; Iftikhar J; Saqib M; Siddique MZ; Imtiaz W
J Coll Physicians Surg Pak; 2022 Aug; 32(8):S147-S149. PubMed ID: 36210677
[TBL] [Abstract][Full Text] [Related]
18. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
Tolliver S; Graham J; Kaffenberger BH
Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
[TBL] [Abstract][Full Text] [Related]
19. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.
Halvorson SA; Gilbert E; Hopkins RS; Liu H; Lopez C; Chu M; Martin M; Sheppard B
J Gen Intern Med; 2013 Nov; 28(11):1525-9. PubMed ID: 23681843
[TBL] [Abstract][Full Text] [Related]
20. Necrolytic migratory erythema: the outermost marker for glucagonoma syndrome.
Gantcheva ML; Broshtilova VK; Lalova AI
Arch Dermatol; 2007 Sep; 143(9):1221-2. PubMed ID: 17875900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
